Cyteir Therapeutics is a leader in the discovery and development of novel therapeutics based on the biology of DNA repair and synthetic lethality for the treatment of cancer and autoimmune diseases. Our initial approach takes advantage of DNA damage overload to induce selective self-destruction of cells by targeting disease-induced RAD51 transport
By precisely modulating DNA, disease cells are overwhelmed by their own DNA damage and undergo cell death
Our lead program targets RAD51, a DNA repair protein that is important in cancer and autoimmune diseases
Leveraging the synthetic lethal paradigm we are developing drugs for use in a range of cancer types
By precision targeting of specific DNA repair proteins, we aim to change the way many autoimmune diseases are treated
Cyteir has developed a screening technology to discover novel DNA repair modulators that induce synthetic lethality in diseases with genetically defined gain-of-function abnormalities
Cancer cells rely on DNA repair for their survival, their ability for rapid and unrestricted growth, and their capacity to rapidly mutate. Because DNA repair is at the center of so many cancer processes, synthetic lethality is a key to Improving treatments for a wide range of cancers.
There are newly discovered roles for DNA repair in the development of autoimmune diseases. Precision targeting of DNA repair mechanisms promises a differentiated synthetic lethal approach to treating a range of autoimmune disorders.